Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.Dineen, T.A., Weiss, M.M., Williamson, T., Acton, P., Babu-Khan, S., Bartberger, M.D., Brown, J., Chen, K., Cheng, Y., Citron, M., Croghan, M.D., Dunn, R.T., Esmay, J., Graceffa, R.F., Harried, S.S., Hickman, D., Hitchcock, S.A., Horne, D.B., Huang, H., Imbeah-Ampiah, R., Judd, T., Kaller, M.R., Kreiman, C.R., La, D.S., Li, V., Lopez, P., Louie, S., Monenschein, H., Nguyen, T.T., Pennington, L.D., San Miguel, T., Sickmier, E.A., Vargas, H.M., Wahl, R.C., Wen, P.H., Whittington, D.A., Wood, S., Xue, Q., Yang, B.H., Patel, V.F., Zhong, W.
(2012) J Med Chem 55: 9025-9044
- PubMed: 22468684
- DOI: 10.1021/jm300118s
- Primary Citation of Related Structures:
- PubMed Abstract:
We have previously shown that hydroxyethylamines can be potent inhibitors of the BACE1 enzyme and that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords compounds (e.g., 1) with sufficient bioavailability ...
We have previously shown that hydroxyethylamines can be potent inhibitors of the BACE1 enzyme and that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords compounds (e.g., 1) with sufficient bioavailability and pharmacokinetic profiles to reduce central amyloid-β peptide (Aβ) levels in wild-type rats following oral dosing. In this article, we describe further modifications of the P1-phenyl ring of the hydroxyethylamine series to afford potent, dual BACE1/CYP 3A4 inhibitors which demonstrate improved penetration into the CNS. Several of these compounds caused robust reduction of Aβ levels in rat CSF and brain following oral dosing, and compound 37 exhibited an improved cardiovascular safety profile relative to 1.
Chemical Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States. email@example.com